Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 184358, 14 pages
http://dx.doi.org/10.1155/2013/184358
Research Article

Qushi Huayu Decoction Inhibits Hepatic Lipid Accumulation by Activating AMP-Activated Protein Kinase In Vivo and In Vitro

1Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, 258 Zhangheng Road, Pudong District, Shanghai 201203, China
2Drug Discovery Laboratory, School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
3Experimental Center for Science and Technology, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
4Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai 201203, China

Received 9 November 2012; Revised 24 January 2013; Accepted 5 February 2013

Academic Editor: Benny Tan Kwong Huat

Copyright © 2013 Qin Feng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. C. Cohen, J. D. Horton, and H. H. Hobbs, “Human fatty liver disease: old questions and new insights,” Science, vol. 332, no. 6037, pp. 1519–1523, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Targher, M. Chonchol, I. Pichiri, and G. Zoppini, “Risk of cardiovascular disease and chronic kidney disease in diabetic patients with non-alcoholic fatty liver disease: just a coincidence?” Journal of Endocrinological Investigation, vol. 34, pp. 544–551, 2011. View at Google Scholar
  3. J. R. Lewis and S. R. Mohanty, “Nonalcoholic fatty liver disease: a review and update,” Digestive Diseases and Sciences, vol. 55, no. 3, pp. 560–578, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. D. M. Torres, C. D. Williams, and S. A. Harrison, “Features, diagnosis, and treatment of nonalcoholic Fatty liver disease,” Clinical Gastroenterology and Hepatology, vol. 10, pp. 837–858, 2012. View at Google Scholar
  5. C. Postic and J. Girard, “The role of the lipogenic pathway in the development of hepatic steatosis,” Diabetes & Metabolism, vol. 34, no. 6, pp. 643–648, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. C. Long and J. R. Zierath, “AMP-activated protein kinase signaling in metabolic regulation,” Journal of Clinical Investigation, vol. 116, no. 7, pp. 1776–1783, 2006. View at Google Scholar · View at Scopus
  7. S. K. Ha, J. Kim, and C. Chae, “Role of AMP-activated protein kinase and adiponectin during development of hepatic steatosis in high-fat diet-induced obesity in rats,” Journal of Comparative Pathology, vol. 145, no. 1, pp. 88–94, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. B. Viollet, M. Foretz, B. Guigas et al., “Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders,” Journal of Physiology, vol. 574, no. 1, pp. 41–53, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Foretz, N. Ancellin, F. Andreelli et al., “Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver,” Diabetes, vol. 54, no. 5, pp. 1331–1339, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. J. D. Browning and J. D. Horton, “Molecular mediators of hepatic steatosis and liver injury,” Journal of Clinical Investigation, vol. 114, no. 2, pp. 147–152, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Guillou, P. G. Martin, and T. Pineau, “Transcriptional regulation of hepatic fatty acid metabolism,” Sub-Cellular Biochemistry, vol. 49, pp. 3–47, 2008. View at Google Scholar · View at Scopus
  12. J. K. Dowman, M. J. Armstrong, J. W. Tomlinson, and P. N. Newsome, “Current therapeutic strategies in non-alcoholic fatty liver disease,” Diabetes, Obesity and Metabolism, vol. 13, no. 8, pp. 692–702, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Mu, J. Du, and P. Liu, “Herbal prescription experience in the treatment of non-alcoholic steatohepatitis of Professor Liu Ping,” Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases, vol. 19, pp. 170–171, 2009. View at Google Scholar
  14. H. Zhang, Q. Feng, H. S. Li et al., “Effects of Qushi Huayu Decoction on cathepsin B and tumor necrosis factor-α expression in rats with non-alcoholic steatohepatitis,” Journal of Chinese Integrative Medicine, vol. 6, no. 9, pp. 928–933, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. Q. Feng, Y. Cheng, Y. Y. Hu, H. Zhang, J. H. Peng, and N. Zhang, “Qushi Huayu Decoction inhibits protein and gene expression of cathepsin B in HepG2 cells induced by free fatty acids,” Chinese Journal of Integrative Medicine, vol. 16, no. 6, pp. 518–524, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. D. E. Kleiner, E. M. Brunt, M. Van Natta et al., “Design and validation of a histological scoring system for nonalcoholic fatty liver disease,” Hepatology, vol. 41, no. 6, pp. 1313–1321, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. Z. Z. Meng, J. H. Hu, J. X. Chen, and G. X. Yue, “Xiaoyaosan decoction, a traditional chinese medicine, inhibits oxidative-stress-induced hippocampus neuron apoptosis in vitro,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 489254, 8 pages, 2012. View at Publisher · View at Google Scholar
  18. J. G. Heider and R. L. Boyett, “The picomole determination of free and total cholesterol in cells in culture,” Journal of Lipid Research, vol. 19, no. 4, pp. 514–518, 1978. View at Google Scholar · View at Scopus
  19. M. Lagouge, C. Argmann, Z. Gerhart-Hines et al., “Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha,” Cell, vol. 127, no. 6, pp. 1109–1122, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. M. S. Lee, C. T. Kim, and Y. Kim, “Green tea (−)-epigallocatechin-3-gallate reduces body weight with regulation of multiple genes expression in adipose tissue of diet-induced obese mice,” Annals of Nutrition and Metabolism, vol. 54, no. 2, pp. 151–157, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. W. S. Kim, Y. S. Lee, S. H. Cha et al., “Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity,” American Journal of Physiology, vol. 296, no. 4, pp. E812–E819, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. A. E. Feldstein, N. W. Werneburg, A. Canbay et al., “Free fatty acids promote hepatic lipotoxicity by stimulating TNF-α expression via a lysosomal pathway,” Hepatology, vol. 40, no. 1, pp. 185–194, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. A. E. Feldstein, N. W. Werneburg, Z. Li, S. F. Bronk, and G. J. Gores, “Bax inhibition protects against free fatty acid-induced lysosomal permeabilization,” American Journal of Physiology, vol. 290, no. 6, pp. G1339–G1346, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Skrobuk, S. von Kraemer, M. M. Semenova, A. Zitting, and H. A. Koistinen, “Acute exposure to resveratrol inhibits AMPK activity in human skeletal muscle cells,” Diabetologia, vol. 55, pp. 3051–3060, 2012. View at Google Scholar
  25. G. M. Do, U. J. Jung, H. J. Park et al., “Resveratrol ameliorates diabetes-related metabolic changes via activation of AMP-activated protein kinase and its downstream targets in db/db mice,” Molecular Nutrition & Food Research, vol. 56, pp. 1282–1291, 2012. View at Google Scholar
  26. J. A. Baur, K. J. Pearson, N. L. Price et al., “Resveratrol improves health and survival of mice on a high-calorie diet,” Nature, vol. 444, no. 7117, pp. 337–342, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. J. A. Vinson, B. R. Burnham, and M. V. Nagendran, “Randomized, double-blind, placebo-controlled, linear dose, crossover study to evaluate the efficacy and safety of a green coffee bean extract in overweight subjects,” Diabetes, Metabolic Syndrome and Obesity, vol. 5, pp. 21–27, 2012. View at Google Scholar
  28. K. Kojima, T. Shimada, Y. Nagareda et al., “Preventive effect of geniposide on metabolic disease status in spontaneously obese type 2 diabetic mice and free fatty acid-treated HepG2 cells,” Biological and Pharmaceutical Bulletin, vol. 34, pp. 1613–1618, 2011. View at Google Scholar
  29. K. W. Ong, A. Hsu, and B. K. Tan, “Chlorogenic acid stimulates glucose transport in skeletal muscle via AMPK activation: a contributor to the beneficial effects of coffee on diabetes,” PLoS ONE, vol. 7, Article ID e32718, 2012. View at Google Scholar
  30. T. Ma, C. Huang, G. Zong et al., “Hepatoprotective effects of geniposide in a rat model of nonalcoholic steatohepatitis,” Journal of Pharmacy and Pharmacology, vol. 63, no. 4, pp. 587–593, 2011. View at Publisher · View at Google Scholar · View at Scopus